CX Institutional Sells 39,807 Shares of Abbott Laboratories $ABT

Key Points

• CX Institutional has reduced its holdings in Abbott Laboratories by 61.5%, selling 39,807 shares and now owning 24,965 shares valued at approximately $3.4 million.
• Abbott Laboratories reported Q2 2025 earnings of $1.26 per share, meeting analyst expectations, and revenue of $11.14 billion, up 7.4% from the previous year.
• The company announced a quarterly dividend of $0.59 per share, with a dividend yield of 1.7% for shareholders of record on October 15th.

CX Institutional decreased its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 61.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 24,965 shares of the healthcare product maker's stock after selling 39,807 shares during the quarter. CX Institutional's holdings in Abbott Laboratories were worth $3,396,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Hughes Financial Services LLC bought a new position in shares of Abbott Laboratories in the first quarter valued at approximately $27,000. Abound Financial LLC bought a new position in shares of Abbott Laboratories in the first quarter valued at approximately $28,000. Elequin Capital LP bought a new position in shares of Abbott Laboratories in the first quarter valued at approximately $30,000. Wormser Freres Gestion bought a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $32,000. Finally, JCIC Asset Management Inc. bought a new position in shares of Abbott Laboratories in the first quarter valued at approximately $32,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Trading Up 1.2%

Shares of ABT stock opened at $136.22 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a market capitalization of $237.09 billion, a PE ratio of 17.07, a price-to-earnings-growth ratio of 2.58 and a beta of 0.69. The business's fifty day moving average is $130.47 and its 200 day moving average is $131.14.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. During the same quarter last year, the business posted $1.14 earnings per share. The firm's revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be issued a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio is presently 29.57%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ABT. Leerink Partnrs raised Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. Leerink Partners initiated coverage on Abbott Laboratories in a report on Monday, June 16th. They issued a "market perform" rating and a $143.00 target price for the company. Raymond James Financial reduced their price objective on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a report on Friday, July 18th. William Blair raised Abbott Laboratories to a "strong-buy" rating in a report on Thursday, July 17th. Finally, Wells Fargo & Company reduced their price objective on Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating for the company in a report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $145.22.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.46% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.